Comprehensive, easy-to-understand information about this condition
How we create this content →Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 6, 2026
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 6, 2026
The documentation for atypical hemolytic-uremic syndrome with I factor anomaly is limited primarily due to the rarity of the condition. As it affects fewer individuals, comprehensive clinical studies and data collection have been challenging. Additionally, the genetic basis of this syndrome has not yet been identified, which further complicates the understanding of its clinical features and management strategies. Despite these challenges, ongoing research may provide new insights in the future.
The clinical picture of atypical hemolytic-uremic syndrome with I factor anomaly includes several key features. Hemolytic-uremic syndrome manifests with symptoms such as acute kidney injury, thrombocytopenia, and hemolytic anemia. Patients may also exhibit decreased levels of circulating complement C3, which is crucial for immune response. Additionally, hypertension is a common finding. These symptoms can significantly impact the patient's health and require careful monitoring and management.
To navigate your care for atypical hemolytic-uremic syndrome with I factor anomaly, consider consulting a nephrologist with expertise in rare kidney disorders. Genetic counseling may also be beneficial, especially given the autosomal dominant inheritance pattern. While there are currently no identified patient organizations, resources such as the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can provide valuable information and support. Additionally, inquire about any available natural history studies that may help contribute to the understanding of this condition.
Currently, there is one active clinical trial related to atypical hemolytic-uremic syndrome with I factor anomaly. This trial may explore potential treatment options or management strategies for the condition. For more details, you can visit the ClinicalTrials.gov website and search for the condition: https://clinicaltrials.gov/search?cond=atypical%20hemolytic-uremic%20syndrome%20with%20I%20factor%20anomaly. Participation in clinical trials may offer access to new therapies and contribute to the understanding of the condition.
Actionable guidance for navigating care for atypical hemolytic-uremic syndrome with I factor anomaly
To navigate your care for atypical hemolytic-uremic syndrome with I factor anomaly, consider consulting a nephrologist with expertise in rare kidney disorders. Genetic counseling may also be beneficial, especially given the autosomal dominant inheritance pattern. While there are currently no identified patient organizations, resources such as the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov can provide valuable information and support. Additionally, inquire about any available natural history studies that may help contribute to the understanding of this condition.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Inheritance patterns describe how genetic conditions are passed from parents to children.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 6, 2026
Consider asking your healthcare providers these condition-specific questions
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
AI-Generated Content: This summary was generated using AI. Always consult with qualified healthcare providers for medical guidance.
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.